In a significant decision with implications for 340B enforcement and False Claims Act (“FCA”) whistleblower litigation, the United States Court of Appeals for the Ninth Circuit (the “Court”) held on March 17, 2026, that a health system (the “System”) may proceed with its qui tam action alleging that pharmaceutical manufacturers engaged in fraudulent price-inflation... READ MORE
Ninth Circuit Permits 340B-Based FCA Claims to Proceed Despite Lack of Private Right of Action
Posted on March 25, 2026 in Health Law News
Published by: Hall Render
